We are on a mission to change the way the world thinks about brain health.
Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.
Our novel technology assesses brain health based on changes in the cellular structure.
Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative diseases.
This gives us the potential to revolutionise how people think about brain health and disease management.
Supporting more efficient drug development and personalised patient care.
Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.
Dr Clifford Jack provides an invaluable reminder to us all on the history of how the NIA-AA framework came into existence, the evolution of the ATN framework and openly talks around the controversial viewpoints for the disease condition. With the upcoming draft review of the NIA-AA Clinical Criteria for Alzheimer’s Disease (AD), it is timely for us all to reflect upon how complex Alzheimer's disease actually is. We look forward to seeing the final version of the updated NIA-AA guideline document soon.
We are pleased to annouce that OBD has been awarded the ISO 13485:2016 Quality standard. Quality of work, standards, processes and people will ensure we reach our goals in supporting clinicians, patients and their families in defeating Alzheimer's disease and other neurodegenerative diseases. Accredited scope of goods or services in respect of which the business is registered: Cortical Disarray Measurement (CDM) software developed to produce measurements of microstructure in the brain, to support a trained medical practitioner to make a diagnosis of Alzheimer’s disease or other neurodegenerative brain conditions.
Rosarium, Amsterdam July 2023 - The event was very well attended and as expected showcased that more work, insights, and visibility is needed to build a stronger evidence base for neurodegeneration measures both in trials and in a clinical setting. Cortical microstructure holds valuable clues and insights that may shed light on some of the mixed results in neurodegeneration we are witnessing with anti-amyloid therapies. A huge thank you to our guest speakers and supporters for making this happen meeting. Dr Jeffrey Cummings Dr Cliff Jack, Prof Nick Fox, Prof Delphine Boche, Dr Michael Irizarry (Eisai), Prof Scott Ayton, Dr Meriel Owen, PhD (ADDF), Dr Ziad Saad (JnJ), Dr Lynne Hughes (GAP), Prof James Nicoll (Southampton)
A fascinating discussion with Dr Holtzman on the role APOE mutation plays in tau meditated neurodegeneration. Valubale insight into the P301S mutant tau transgenic mice (PS19) model and also acknowlegements that more work needs to be done on having better biomarkers of neuroimflammation as this fields gathers more focus and momentum.